Related Experiment Video
Updated: Jun 27, 2026

Sodium Taurocholate Induced Severe Acute Pancreatitis in C57BL/6 Mice
Published on: June 28, 2021
Triglyceride Threshold for Intensive Lipid-Lowering Therapy in Acute Hyper-Triglyceridemic Pancreatitis: A
Meiling Yu1,2, Enqiang Mao1, Yanyan Xu2,3
1Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Abstract:
Background: The prognostic significance of early triglyceride (TG) reduction in hyper-triglyceridemic acute pancreatitis (HTG-AP) remains controversial. This study aimed to investigate the association between admission TG levels, early TG goal achievement, and clinical outcomes in patients with HTG-AP. Methods: This retrospective study included 345 patients with HTG-AP. Early TG goal achievement was defined as TG ≤ 5.65 mmol/L within 72 h of admission. Disease severity was classified according to the Revised Atlanta Classification. Associations between TG parameters and outcomes were analyzed using ordinal logistic regression. Results: No significant differences were observed between the goal-achieved (n = 274) and non-goal-achieved (n = 71) groups regarding pancreatic necrosis, hospital stay, or in-hospital mortality. Admission TG levels demonstrated that the highest TG levels did not correspond to the most severe disease course. Compared to patients with admission TG > 90.4 mmol/L, those with TG levels between 11.3 and 56.5 mmol/L had significantly lower odds of more severe disease, while no significant differences were found for TG levels between 56.5 and 90.4 mmol/L. Neither admission TG levels nor the degree of TG reduction within 72 h was significantly correlated with pancreatic necrosis. Conclusions: Early TG goal achievement was not associated with improved clinical outcomes in patients with HTG-AP. The routine use of aggressive early lipid-lowering therapy requires further validation before it can be routinely recommended. TG ≥ 56.5 mmol/L might represent a threshold for disease progression risk. Further studies are needed to determine the clinically meaningful cutoff value.
More Related Videos
07:10Establishment of a Mouse Severe Acute Pancreatitis Model using Retrograde Injection of Sodium Taurocholate into the Biliopancreatic Duct
Published on: April 1, 2022
07:38Preparing a Mice Model of Severe Acute Pancreatitis via a Combination of Caerulein and Lipopolysaccharide Intraperitoneal Injection
Published on: May 10, 2024
Related Concept Videos
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acute Pancreatitis II: Pathophysiology
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...